Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board

• Former Chief Scientific Officer & President of R&D at Pfizer, Dr. Mikael Dolsten brings decades of R&D and strategic leadership experience in pharmaceutical medicine to guide Marengo's next phase of growth and value creation
  
  
• World-renowned oncology expert and Director of the Vall d'Hebron Institute of Oncology (VHIO), Dr. Josep Tabernero joins SAB to advise on clinical development of Marengo's novel immunotherapies for their broad potential across multiple tumor types including CRC, GEJ and NSCLC

CAMBRIDGE, Mass., July 31, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent member of its Board of Directors, and Josep Tabernero, M.D., Ph.D., to its Scientific Advisory Board (SAB).

"We are honored to welcome both Mikael and Josep to Marengo at this transformative time," said Zhen Su, M.D., M.B.A., Chief Executive Officer of Marengo Therapeutics. "Mikael's decades of leadership in advancing innovative medicines will be invaluable as we strategically grow our pipeline, and Josep's deep expertise in clinical trial and GI cancers comes at a pivotal time as we advance invikafusp alfa and expand our clinical programs."

Dr. Dolsten most recently served as Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer Inc., where he led global R&D strategy and portfolio advancement for more than 16 years. A physician–scientist and biopharma leader, Dr. Dolsten has been instrumental in the development of breakthrough innovations spanning small molecules, biologics, gene therapies, and vaccines—including leading Pfizer's scientific response to the COVID-19 pandemic. His leadership has shaped portfolios at Boehringer Ingelheim, AstraZeneca, and Wyeth, and he has contributed to corporate transactions exceeding $100 billion in value. He has also contributed to more than 36 drug approvals, many representing breakthroughs in the oncology field, during his tenure as leader of Pfizer global R&D-Medical.

Dr. Dolsten currently serves on the public boards of Agilent Technologies and Rocket Pharmaceuticals and holds advisory roles with leading investment and innovation groups including Blackstone Life Sciences, GV (formerly Google Ventures), Bain & Company, and Formation Bio. He also advises and serves on the boards of several private biotechnology companies, including Arbor Biotechnologies, Orbis Medicines, Immunai, FairJourney Biologics, Orogen Therapeutics, Quarry Thera, and Chai Discovery. He is a Visiting Professor at Lund University and a member of the Royal Swedish Academy of Engineering Sciences, and he has advised U.S. and U.K. leadership on public health and pandemic preparedness.

"I am excited to join Marengo's Board at this pivotal inflection point in its clinical investigation and deployment of its powerful platform technologies," said Mikael Dolsten, M.D., Ph.D. "The company's unique approach to precision T cell activation has the potential to deliver first-in-class and best-in-class immunotherapies for patients with difficult-to-treat cancers, and I look forward to contributing to the advancement of its uniquely innovative pipeline."

Dr. Tabernero, Head of the Medical Oncology Department and Director of VHIO in Barcelona, is recognized globally for his contributions to cancer research and leadership, particularly in the areas of gastrointestinal cancers and early-phase oncology drug development. He served as President of the European Society for Medical Oncology (ESMO) from 2018–2019 and has been an active member of its Executive Board and multiple educational and scientific committees within ESMO, ASCO, and AACR. He currently serves as the Chair of Cancer Core Europe and as a member of the Board of Directors of the Organization of European Cancer Institutes (OECI). Dr. Tabernero has (co)-authored approximately 600 peer-reviewed papers with an H-Index of 115, and he currently serves on the editorial boards of leading oncology journals including Annals of Oncology, ESMO Open, Cancer Discovery, Clinical Cancer Research, Cancer Treatment Reviews, and Nature Reviews Clinical Oncology, as well as on the scientific advisory boards of several major pharmaceutical and biotechnology companies.

"The clinical signals observed in the ongoing Phase I/II study with invikafusp alfa as a single agent in colorectal cancer, gastroesophageal junction tumors, NSCLC, and other indications are highly encouraging," Dr. Tabernero said. "I look forward to working with the Marengo team to guide further development of this promising selective T cell agonist platform as a new class of IO backbone that promises to bring more treatment options to patients."

About Marengo Therapeutics
Marengo Therapeutics, Inc., a clinical-stage biotech company, develops novel TCR-targeting antibodies that selectively modulate common and disease-specific T cell subsets of the germline TCR repertoire to provide lifelong protection against cancer and autoimmune diseases. With a passionate team of dedicated scientists experienced in immunology and oncology, and three proprietary platforms: Selective T Cell Activation Repertoire (STAR), Trispecific T Cell Engager (Tri-STAR) and T cell Depletor (MSTAR), Marengo is working to selectively target the right T cells in the right patients to create a world in which everyone's immune system can defeat cancer and autoimmune diseases. To learn more, visit marengotx.com.

About the STAR™ Platform
Marengo's STAR™ Platform is a multi-specific antibody-fusion platform derived from Marengo's proprietary library of antibodies targeting germline-encoded variable Vβ regions of the TCR fused to different T cell co-stimulatory moieties. Combining a novel non-clonal mode of TCR activation with a T cell co-stimulator in the same molecule promotes a distinct mechanism of action that promotes durable anti-tumor Vβ T cell responses.

About Invikafusp alfa (STAR0602)
Invikafusp alfa (STAR0602) is the lead candidate from Marengo's STAR™ platform. It is designed to selectively activate a common Vβ T cell subset found in all cancers by combining a non-clonal mode of TCR activation with a T cell co-stimulatory signal in a single molecule. This innovative approach promotes the expansion of clonally diverse, effector memory Vβ T cells, enhancing anti-tumor immunity and enabling durable tumor clearance. Extensive preclinical studies demonstrate STAR0602's potent anti-tumor activity in both mouse and human ex vivo models via a novel mechanism of action.

Marengo Contacts:

Media
Peg Rusconi | [email protected]

Investors
Svetlana Makhni | [email protected]

SOURCE Marengo Therapeutics